Voloshyna, N <br/><br/>
Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.  [electronic resource] 

 -  European journal of neurology  Mar 2015 
 - 570-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-1331 
<br/><br/><label>Standard No.: </label>10.1111/ene.12618  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Exercise Test<br/>Female<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Male<br/>Middle Aged<br/>Mobility Limitation<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Natalizumab--administration & dosage<br/>Outcome Assessment, Health Care<br/>Prospective Studies<br/>Retrospective Studies<br/>Severity of Illness Index<br/>Walking--physiology